TENK SEC filings, in plain English
Everything TenX Keane Acquisition has filed with the SEC that we hold — 40 filings, newest first, 5 with a plain-English summary of what changed and why it matters. Every row links to the primary document on EDGAR, so you can check the source rather than trust us.
The feed
live EDGAR captureNew filings appear here within minutes of hitting EDGAR; summaries follow once the pipeline has read them.
What changed: The filing is a Definitive Proxy Statement (DEF 14A) for Citius Oncology, Inc. regarding its 2026 Annual Meeting of Stockholders scheduled for September 29, 2026. It does not contain SPAC redemption deadlines or trust value updates as the SPAC TenX Keane Acquisition status is CLOSED; instead, it reports on corporate governance and executive compensation matters. Key disclosures include: 1) Election of three Class II directors (Dr. Eugene Holuka, Robert Smith, Carol Webb) to serve until the 2029 Annual Meeting. 2) Ratification of Wolf Company, P.C. as the independent auditor for the fiscal year ending September 30, 2026. 3) Executive compensation details for Named Executive Officers Leonard Mazur, Myron Holubiak, and Myron Czuczman, including base salaries ($166,250 for Mazur; $450,000 for Holubiak; $225,000 for Czuczman in FY2025) and equity awards valued at $2,975,000, $1,487,500, and $1,443,750 respectively. 4) A related-party transaction update regarding an unsecured promissory note from Citius Pharma, amended on May 4, 2026, to change maturity triggers to require $50 million in gross proceeds or senior debt repayment, with a voluntary conversion feature at $0.90 per share. 5) Security ownership data showing Citius Pharmaceuticals, Inc. holds 71.0% of outstanding shares as of August 17, 2026. Why it matters: Investors tracking sponsor conduct and deal progress should note that while the SPAC shell is closed, the operating company (Citius Oncology) continues to manage significant related-party dependencies, evidenced by the amended promissory note terms which tie repayment to future capital raises or monetization events. The proxy statement confirms board continuity and auditor retention, but highlights high insider ownership concentration (71.0% by Citius Pharma) and substantial equity-based compensation for executives, which may impact shareholder dilution and alignment of interests. The filing provides the specific record date (August 17, 2026) and voting procedures for the upcoming annual meeting, which is the primary mechanism for shareholder oversight in this closed-SPAC structure.
What changed: The 10-Q filed under Commission file number 001-41534 is that of Citius Oncology, Inc. for the quarter ended June 30, 2026, on a September 30 fiscal year. Cash rose to $16,563,705 from $3,924,908 at September 30, 2025 and total current assets to $42,707,165 from $27,542,881, with inventory of $22,625,945; in-process research and development net of amortization fell to $69,385,938 from $73,400,000 and total assets were $112,093,103. Why it matters: Cash quadrupled while current liabilities grew $9.3 million, and the going-concern paragraph and the Nasdaq compliance question are both still live on the record. The two share counts are struck on different bases — the balance-sheet figure and the cover figure are not comparable and neither should be read as a change in outstanding shares.
combination deadline, going-concern doubtnothing moved · 2 with no prior record of ours
- Combination deadline
- 2031-01-20 · unchanged
- Going-concern doubt
- stated · unchanged
The clause …“5,142,858 warrants to $ 1.09 per share and extended the expiration date to January 20, 2031 . Gross proceeds from the offering were approximately $ 9.0 million and net proceeds were $ 7,619,854 , after deducting placement agent fees”…
The clause …“firm’s report includes an explanatory paragraph stating that there is substantial doubt about our ability to continue as a going concern; ● our need for substantial additional funds and our ability to raise those funds; ● our”…
Read from stored SEC filing text by a regex — no model is involved — and each side links to the filing it came from. “Not previously extracted” is a statement about our record, not about the company: the clause may be present in wording we do not match.
What changed: Citius Oncology, Inc. (Nasdaq: CTOR) issued a press release dated August 14, 2026 reporting its fiscal third quarter ended June 30, 2026. Revenue was $1.5 million for the three months and $7.1 million for the nine months, against no revenue in either prior-year period, with gross profit of $1.0 million and $5.5 million. General and administrative expense was $4.2 million for the quarter against $1.9 million a year earlier, and $30.7 million for the nine months including a $19.7 million one-time CMO contract cancellation charge recognized in the second fiscal quarter. Why it matters: The $16.6 million cash balance is the product of a warrant exercise and a debt draw, not of the $1.5 million quarter, and $15.0 million of the term facility remains undrawn. The company states explicitly that it recognizes revenue when wholesaler orders are fulfilled, so the institutional vial counts lead reported revenue rather than equalling it.
What changed: On August 7, 2026, Citius Oncology, Inc. (post-merger entity from TenX Keane Acquisition) expanded its Board to nine directors and appointed Jonathan Peri, Ph.D., J.D. as a Class I independent director, effective August 10, 2026, serving until the 2028 annual meeting. Why it matters: This is a routine post-closing board expansion for the combined company with no impact on trust value, redemptions, or deal terms; it signals normal governance activity at the merged entity.
What changed: Exhibit 99.1 to an 8-K of Citius Oncology, Inc. (Nasdaq: CTOR): an August 5, 2026 press release updating on the commercial launch of LYMPHIR (denileukin diftitox-cxdl), which the FDA approved and which launched in the U.S. in December 2025 for relapsed or refractory Stage I–III cutaneous T-cell lymphoma after at least one prior systemic therapy. LYMPHIR is now available in 42 institutions; the number of new institutions ordering rose 78% quarter over quarter and vials ordered by institutions from wholesalers rose 31% during the quarter ended June 30, 2026. Why it matters: All the growth figures are counts of ordering institutions and vials rather than revenue, and the $400 million market size and payer coverage are company estimates. The release also states the company is working to regain Nasdaq listing compliance and to secure a new bulk drug substance supplier.
combination deadline, going-concern doubtnothing moved · 2 with no prior record of ours
- Combination deadline
- not previously extracted2031-01-20
- Going-concern doubt
- stated · unchanged
The clause …“5,142,858 warrants to $ 1.09 per share and extended the expiration date to January 20, 2031 . Gross proceeds from the offering were approximately $ 9.0 million and net proceeds were $ 7,619,854 , after deducting placement agent fees”…
The clause …“firm’s report includes an explanatory paragraph stating that there is substantial doubt about our ability to continue as a going concern; ● our need for substantial additional funds and our ability to raise those funds; ● our”…
Read from stored SEC filing text by a regex — no model is involved — and each side links to the filing it came from. “Not previously extracted” is a statement about our record, not about the company: the clause may be present in wording we do not match.
going-concern doubtnothing moved · 1 with no prior record of ours
- Going-concern doubt
- stated · unchanged
The clause …“firm’s report includes an explanatory paragraph stating that there is substantial doubt about our ability to continue as a going concern; ● our need for substantial additional funds and our ability to raise those funds; ● our”…
Read from stored SEC filing text by a regex — no model is involved — and each side links to the filing it came from. “Not previously extracted” is a statement about our record, not about the company: the clause may be present in wording we do not match.
going-concern doubt, mandate languagenothing moved · 2 with no prior record of ours
- Going-concern doubt
- stated · unchanged
- Mandate language
- we intend to pursue within the territory.… · unchanged
The clause …“firm’s report includes an explanatory paragraph stating that there is substantial doubt about our ability to continue as a going concern; ● our need for substantial additional funds and its ability to raise those funds; ● our”…
Read from stored SEC filing text by a regex — no model is involved — and each side links to the filing it came from. “Not previously extracted” is a statement about our record, not about the company: the clause may be present in wording we do not match.
In plain English
Redemption deadlinethe last day to hand shares back for cash
Set by the filing that calls the meeting. Tender after it and the company is under no obligation to pay you the trust value.
Cash in trust / trust per sharethe cash the company is holding for each public share
Filed quarterly in the 10-Q's XBRL. It earns interest between filings, so the figure on a given day is slightly higher than the last filed one — where we show that we label it an estimate.
Accession numberthe SEC's unique id for one filing
Every figure on this page carries the accession of the filing that states it, so you can open the primary document rather than trust us.